ÂÜÀòÂÒÂ×

Madeline Farley, Ph.D., currently serves as the Chief Scientific Officer for the Biochemistry and Bioanalytical Division at Genesis Drug Discovery & Development (GD³) since July 2021, where responsibilities include leading services for preclinical drug discovery across various therapeutic areas. Previously, Madeline held roles as Managing Director and Senior Scientist, focusing on the development and execution of various assays and project management. Madeline's academic experience includes a postdoctoral researcher role at Baylor College of Medicine, leading research on retinal ganglion cell injury and signaling, and postdoctoral training in macromolecular structural biology at the University of Texas Medical School at Houston. Madeline obtained a Ph.D. in Cellular and Molecular Neuroscience from The University of Texas Health Science Center at Houston and a B.S. in Biochemistry with a Mathematics minor from Centenary College of Louisiana.